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Background: The purpose of using preventative inhaled treatments in cystic fibrosis is to 
improve health outcomes. Therefore, understanding the relationship between adherence to 
treatment and health outcome is crucial. Temporal variability, as well as absolute magnitude of 
adherence affects health outcomes, and there is likely to be a threshold effect in the relationship 
between adherence and outcomes. We therefore propose a pragmatic algorithm-based cluster-
ing method of objective nebulizer adherence data to better understand this relationship, and 
potentially, to guide clinical decisions.
Methods to cluster adherence data: This clustering method consists of three related steps. 
The first step is to split adherence data for the previous 12 months into four 3-monthly sections. 
The second step is to calculate mean adherence for each section and to score the section based 
on mean adherence. The third step is to aggregate the individual scores to determine the final 
cluster (“cluster 1” = very low adherence; “cluster 2” = low adherence; “cluster 3” = moderate 
adherence; “cluster 4” = high adherence), and taking into account adherence trend as represented 
by sequential individual scores. The individual scores should be displayed along with the final 
cluster for clinicians to fully understand the adherence data.
Three illustrative cases: We present three cases to illustrate the use of the proposed clustering 
method.
Conclusion: This pragmatic clustering method can deal with adherence data of variable 
duration (ie, can be used even if 12 months’ worth of data are unavailable) and can cluster 
adherence data in real time. Empirical support for some of the clustering parameters is not 
yet available, but the suggested classifications provide a structure to investigate parameters in 
future prospective datasets in which there are accurate measurements of nebulizer adherence 
and health outcomes.
Keywords: cystic fibrosis, medication adherence, nebulizers and vaporizers, epidemiologic 
methods, cluster analysis
Introduction
Cystic fibrosis (CF) is a multisystem condition due to a genetic defect resulting in 
dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein.1 
The lungs are the main organ affected – people with CF are vulnerable to recurrent 
infection, which leads to progressive lung damage and respiratory failure.1 Median 
survival has improved from ~6 months when CF was first recognized in 1938 to 
around 45–50 years due to improved treatment options and quality of care,2,3 but ~80% 
of all mortality in CF is still due to respiratory failure.4 An important maintenance 
treatment in CF is therefore inhaled therapies typically consisting of nebulized 
antibiotics and mucolytics, which have been proven to be efficacious in maintaining 
lung health.5,6 We have described this as “efficacious” rather than “effective”, since 
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adherence in randomized controlled trials is 80%–100%,7 
whereas real world data among adults with CF suggest that 
adherence is less than 50%.8,9 Such low levels of adherence 
limit the benefits derived from the new inhaled therapies 
that have been introduced over the past 20 years, despite 
the efforts of clinicians who are prescribing more of these 
to people with CF.10,11
The importance of increasing adherence to inhaled 
therapies is widely recognized among the CF community.12 
An important step in developing strategies to improve adher-
ence is the accurate quantification of adherence level, so that 
change can be measured and understood.13 In CF, the tech-
nology to accurately capture date- and time-stamped objec-
tive adherence data with tamper-proof chipped nebulizers 
is available for clinical use.14,15 However, data still need to be 
analyzed with the appropriate methods to quantify adherence 
accurately. We have recently published a methodology paper 
to explain the methods of calculating “normative adherence”, 
which better reflects treatment effectiveness compared to 
unadjusted adherence, by taking into account characteristics 
of a person with CF when defining the minimum required 
treatment regime.16 In this paper, we explain the rationale 
for clustering adherence data and present a pragmatic, 
algorithm-based method for clustering objective adherence 
data downloaded from chipped nebulizers.
We acknowledge that clustering will typically involve 
judgment, and different judgments may create different 
clusters. We have made judgments driven by a pragmatic 
approach to data that allow data to be clustered readily in 
routine practice with the aim of generating a systematic clus-
tering strategy, that then can be subjected to empirical testing 
in prospective data and a paper doing this will follow.
the purpose of clustering adherence data
Nebulizer adherence is a behavior, and the study of behavior 
has traditionally involved either group-level comparison 
(nomothetic approach) or analysis of individual-level 
longitudinal data (idiographic approach).17 Each approach 
has advantages and disadvantages. The nomothetic approach 
allows us to understand average behavior across the 
population.18 However, the average group result may conceal 
important granular details crucial to the understanding of the 
behavior of individuals,18 hence the increasing interest in 
the use of idiographic approach within health psychology.19 
Although everyone may have unique behavioral patterns, 
clustering offers a compromise between the nomothetic 
and idiographic approaches, by identifying individuals with 
patterns of behavior that can be mapped within homogenous 
subgroups (clusters) that can accommodate a number of 
individuals with patterns that are similar enough to allow 
meaningful groupings.18 This allows homogenous subgroups 
to be studied, which may identify generalizable trends with 
a better understanding of how that relates to the group and 
to individuals.
Clustering of objective nebulizer adherence would 
involve the categorization of continuous data. This may 
be perceived as wasting valuable information and reduc-
ing statistical power for comparison.20 However, it has 
been argued that loss of information is small if there is an 
adequate number of categories to represent the continuous 
variable.20 A common reason for categorizing a continu-
ous variable is to study the association between variables 
that are not linearly related.21 The fundamental purpose for 
supporting nebulizer adherence among adults with CF is to 
improve health outcomes, yet there is most likely a threshold 
effect for nebulizer adherence in relation to health outcomes. 
Increasing adherence from 1% to 5% would be a 5-fold 
increase, yet such a low level of adherence is not associated 
with good health outcomes.9,22 Similarly, a 5-fold increase in 
adherence from 90% to 450% is unlikely to give additional 
benefits. However, a 5-fold increase in adherence from 20% 
to 100% is very likely to have clinical benefits by reducing 
the frequency of pulmonary exacerbations and decreas-
ing healthcare costs.9,22 Given the likely threshold effect 
of nebulizer adherence, clustering adherence data makes 
sense when we are analyzing data, to better understand the 
relationship between adherence levels and the expected 
health benefits. Indeed, it is anticipated that clustering of 
adherence data will allow more meaningful levels of adher-
ence targets to be set by helping us to understand how much 
treatment is enough. In addition, adherence clusters might 
well allow clinicians to make a better judgment of the cause 
for deterioration in lung health based on objective nebulizer 
adherence data.
Previous studies have demonstrated that health benefits 
of medication adherence are likely to depend on both the 
magnitude and the variability of adherence.23,24 Yet, adher-
ence levels are typically quantified in terms of the magnitude 
only, partly because some methods of capturing adherence 
data, eg, pharmacy refill data, could not identify variation 
in medication use.25 The availability of tamper-proof 
chipped nebulizers in CF means that detailed date- and time-
stamped adherence data are available to study the pattern of 
adherence.26 We provide examples of different time-series 
adherence patterns in Figure 1 to highlight the importance 
of quantifying both the magnitude and the variability in 
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adherence. By identifying different clusters of adherence pat-
tern taking into account both the magnitude and variability, 
there is potential for determining the level of adherence that 
is needed to improve health outcomes, or to potentially target 
appropriate adherence interventions.
Criteria for the methods used to cluster 
adherence data
Several methods are available for clustering time-series 
adherence data,27 and the purpose of clustering should be 
taken into account when selecting the appropriate clustering 
method. Given that the magnitude and variability of adher-
ence may influence health outcomes, it will be important that 
both magnitude and variability are taken into account in the 
clustering method.
For a clustering method to help guide day-to-day clinical 
management of people with CF (eg, by setting an adherence 
target or in understanding the likely contribution of nebulizer 
adherence to lung function decline in someone reviewed in 
a CF clinic), an important practical consideration is the abil-
ity to cluster adherence data in real time. Another equally 
important consideration is to avoid a clustering method 
where the addition of data from new subjects could alter 
the cluster of previously clustered subjects. Finally, the 
clustering method will be most useful if it can be applied 
for all available adherence data. For example, if a clustering 
method required 12 months of data – not everyone will have 
complete annual adherence data – some may be started on 
inhaled treatment in the middle of the year, and missing 
data may occasionally occur, eg, due to machine malfunc-
tion or saturation of electronic data capture capacity. Data 
imputation to infer complete annual adherence is difficult 
since data are not missing at random.28 Since adherence in 
long-term conditions will tend to decrease with time,29,30 
when only a short duration of data are available there is 
a risk of overestimating the long-term adherence rate. In 
Figure 2, we illustrate an example of high adherence level 
following initiation of inhaled therapy that then declined, 
demonstrating the potential for error if short runs of adher-
ence data are used to infer overall steady state or customary 
adherence. We have chosen to use a minimum period of 
3 months to ensure that the adherence classification takes 
into account a period of time that is long enough to reflect 
a meaningful period of adherence behavior likely to have 
a reasonable probability of having some relationship with 
lung health.
??????????????
???
????
????
??
??
??
??
??
???
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
???????????????
????
????
?
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
???
????
????
??
??
?
??
??
??
???
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
????
??????????????
???
????
????
??
??
???????????????????? ???????????????????????????????????????????????????????????????????????????????????????????? ????????????????????????? ?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ?????
??
??
???
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
??????????????
???
????
????
??
??
?
??
??
??
???
????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????
Figure 1 examples of time-series adherence charts to highlight the importance of considering both the magnitude and the variability of adherence.
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Processing time-series adherence data 
for clustering
All clustering methods require a clustering technique/ 
algorithm and the relevant variables from a dataset for 
clustering. For time-series data, there are three broad 
approaches to “process” the variables for clustering: use the 
actual time-series pattern (ie, raw data-based), use summary 
measures derived from the time-series data (ie, feature-based), 
and use model parameters from time-series data or identify 
different time-series model (ie, model-based).31
existing techniques to cluster 
“processed” time-series adherence data
Most clustering techniques can be applied for any of the 
three approaches for processing time-series data. Several 
techniques for clustering data exist.
An example of a data-driven clustering technique is the 
“principal components analysis” (PCA), which uses orthogo-
nal transformations to combine a group of correlated variables 
into linear functions of these which are uncorrelated.32 PCA 
has also been applied to time-series adherence data to iden-
tify different adherence clusters33 and can work with either 
of the three different variable approaches. An argument to 
support the use of data-driven clustering methods is the lack 
of need for a priori assumptions which may introduce bias. 
However, it is important to note that assumptions are still 
needed in terms of deciding which variables are clinically 
important enough to be analyzed with the data-driven cluster-
ing method. Indeed, three different studies aiming to identify 
phenotypes of COPD using different clinical variables have 
yielded different groups of clusters.34 It should be noted that 
the generation of different clusters is not necessarily a prob-
lem if the clusters’ validity in terms of predicting outcomes 
can be empirically tested in prospective datasets. Hence the 
main issue is identifying a rational and reproducible approach 
to generate clusters that can be used in clinical practice, and is 
then suitable for empirical confirmation in prospective data-
sets. Data-driven methods also tend to require complete data 
for cluster analysis (eg, only 92 of the 124 eligible partici-
pants in the study by Yeo et al were analyzed due to missing 
data),33 which is a disadvantage when nebulizer adherence 
datasets are of varying duration and imputation is difficult 
due to the missing not at random nature of adherence data. 
Perhaps the biggest disadvantage of a data-driven clustering 
technique is with clustering data from new subjects in real 
time. Regularly repeating the clustering process with the 
introduction of any data from new subjects is not an option, 
since that could assign a previously clustered dataset to 
new clusters. Therefore, the only practical way to use data-
driven clustering methods in a clinical context is to cluster 
a representative sample of adherence dataset to generate 
rules to define newly acquired adherence data into existing 
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Figure 2 An example of the impact of using different data duration to infer the annual adherence level.
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clusters. However, rules based on time-series pattern (or even 
time-series summary measures) may not be straightforward 
to apply, so this would introduce subjectivity in defining the 
cluster for new adherence data and also potentially result 
in difficulty of dealing with new adherence data that were 
deemed “unclassifiable” within the existing rules.
There are also other data-driven clustering techniques 
designed specifically to deal with time-series adherence data. 
An example is the Typology of Temporal Patterns approach, 
which uses dynamic cluster analysis to identify different 
adherence clusters based on the raw treatment adherence 
time-series pattern.18 However, the methods also have similar 
disadvantages to using PCA to cluster time-series adherence 
data, ie, the need for equal adherence data duration, and it is 
difficult to perform the clustering in real time.
An alternative clustering technique for time-series data 
is using visual inspection to identify different adherence 
patterns.35 Visual inspection could be criticized as being 
subjective, but is used in practice, eg, almost all radiology 
images are read and interpreted by clinicians based on pattern 
recognition from visual inspection.36 This is nonetheless a 
labor-intensive process that also requires significant invest-
ment in staff training in order to reliably cluster adherence 
data with visual inspection. Whilst some adherence patterns 
are relatively easy to identify with visual inspection, there are 
other more ambiguous patterns whereby visual inspection is 
less useful (Figure 3).
A brief description of our proposed 
adherence data clustering method
Given the limitations of the current available techniques to 
cluster objective nebulizer adherence data, we propose an 
algorithm-based clustering method which is able to handle 
adherence data of varying duration (including dataset with 
missing data) without the need for imputation. The proposed 
method also allows for real-time clustering of new adherence 
data, taking into account both the magnitude and variation in 
adherence. The clustering method consists of three separate 
steps, which we describe in the next section. We also provide 
exemplar cases to illustrate how the proposed clustering 
method can be applied.
As outlined previously, there is no perfect way to cluster 
adherence data in a clinical context, however, the approach 
we have adopted allows us to use reproducible methods 
to generate adherence clusters that can then be explored 
empirically in prospective datasets in terms of the relation-
ship between adherence and health outcomes (eg, frequency 
of pulmonary exacerbations).
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
???
????
????
??????
????
???
??????????????
???
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
???
????
????
??????
????
???
??????????????
???
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
?
??
??
??
??
???
???????????????????????????
??????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????
?????????????????????????
??????????????
???
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
??
????
????
???
????
????
??????
????
???
??????????????
???
????
????
??
Figure 3 Examples of adherence patterns that are relatively easy and those that are more difficult to identify with visual inspection.
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Figure 4 Summary of the steps involved in clustering adherence data using our proposed algorithm-based technique.
Notes: It is important to display both the detailed scores for each section and the overall cluster for the data, so that the overall cluster can be interpreted accurately. In 
this example, the overall adherence is low, but the adherence is improving with time over a 9-month period from January to September 2015.
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Using an algorithm-based method 
to cluster objective nebulizer 
adherence data
We describe each step involved in clustering adherence 
data using our proposed algorithm-based method and sum-
marize the steps involved in Figure 4. The time-series charts 
displayed in Figure 4 are for illustrative purpose only – 
adherence data can be clustered with the described method 
by calculating normative adherence for 3-monthly sections 
without plotting time-series charts.
Step 1: splitting the previous 12 months 
of adherence data into 3-monthly 
sections
Splitting annual adherence data into four 3-monthly sections 
is an empirical approach that balances the tension between 
detecting variation in adherence over time, whilst sampling 
enough sustained behavior to create an expectation that the 
behavior might be related to other downstream effects such 
as lung health. It also allows people who have less data 
to be clustered using the same technique with a minimum 
data capture period of only 12 weeks required to classify 
people’s behavior.
The 3-monthly period represents a good compromise 
between detail and practicality. Shorter periods of adher-
ence (eg, monthly) preserves more information but as 
demonstrated in Figure 2, short runs of adherence data may 
poorly reflect the underlying adherence patterns that might 
be expected to relate to more distal outcomes such as lung 
health. For example, short time periods may be prone to 
overestimating underlying adherence if particularly good 
periods of adherence, eg, when people are hospitalized, com-
prise most of the relatively short segment of data analyzed. 
On the other hand, splitting the adherence data into longer 
periods (eg, 6 months) would produce insufficient numbers 
of sections to understand the variation of adherence over a 
1-year period and also mean ignoring a subgroup of people 
with only 3–6 months’ worth of adherence data in any given 
1-year period.
Step 2: assigning each 3-month section 
with a score for the mean adherence 
level of that section
The mean normative adherence16 for each 3-monthly sec-
tion should be calculated. This allows each section to be 
scored based on mean adherence, with mean adherence of 0 
to 25% assigned a score of “1”, mean adherence of 25.1% 
to 50% assigned a score of “2”, mean adherence of 50.1% to 
75% assigned a score of “3”, and mean adherence of 75.1% 
or above assigned a score of “4”.
Step 3: aggregating the scores of each 
3-monthly section to determine the final 
cluster and displaying the results
People with 12 months of adherence data over the previous 
year will thus have four sections, while people with 3 months 
of adherence data will have one section. The mean score for 
all the sections in the previous year is grouped to determine 
the adherence cluster. A mean score of 1 defines cluster “1”. 
A mean score of .1 but ,3 defines cluster “2”. A mean 
score of $3 to ,4 defines cluster “3”. A mean of score of 4 
defines cluster “4”. In effect, all the mean scores are rounded 
down to the nearest whole number to determine the overall 
cluster, except for scores between 1.1 and 1.9 that were 
rounded up to “2”. The purpose of aggregating the scores in 
this manner is to separate the group with consistently high 
adherence (cluster “4” can only be achieved if all sections 
are scored “4”) and the group with consistently low adher-
ence (cluster “1” can only be achieved if all sections are 
scored “1”). This is consistent with the groups that are easily 
identifiable with visual inspection of time-series pattern as 
described in Figure 3.
We recognize that those with moderate adherence (clus-
ters “2” and “3”) may well display a trend of increasing or 
decreasing adherence with time. The trend is relevant for cli-
nicians when monitoring the adherence of people with CF. For 
example, people with declining adherence require diagnosis 
for the cause of adherence decline and the necessary interven-
tion, whereas people with a trend of improving adherence may 
only require regular adherence feedback and encouragement. 
The trend can be understood if all the individual scores for 
each section are displayed along with the overall cluster score. 
For example, someone with sequential section scores of “1”, 
“2”, “2”, and “3” would have an overall cluster labeled “2”, 
and the trend of improving adherence is apparent. On the other 
hand, someone with sequential section scores of “4”, “4”, “2”, 
and “1” would also have an overall cluster labeled “2”, but 
a trend of declining adherence is present. For convenience, 
an improving trend can be denoted with a “+” sign after the 
cluster number and a declining trend can be denoted with “-” 
sign whilst the “o” sign can be used to denote the lack of any 
obvious trend. The person with sequential section scores of 
“1”, “2”, “2”, and “3” would therefore be in cluster “2(+)”, 
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whilst the person with sequential section scores of “4”, “4”, 
“2”, and “1” would therefore be in cluster “2(-)”. By taking 
into account the possible adherence trends for clusters “2” and 
“3”, there are in effect eight different clusters – “1”, “2(-)”, 
“2(o)”, “2(+)”,“3(-)”, “3(o)”, “3(+)”, and “4”. However, in 
terms of analyzing the effect of adherence on health outcomes, 
we anticipate that only four different clusters (“1” to “4”) 
matter, since the number of exacerbations will probably even 
out over a 1-year period (those with declining adherence are 
more likely to have exacerbations during the latter part of the 
period, while those with improving adherence are more likely 
to have exacerbations during the earlier part of the period).
Another important reason for displaying all the individual 
section scores is to make clear the amount of adherence data 
that are available for the previous 12 months, so that clini-
cians can make a better judgment regarding the adherence 
status of a person with CF. For example, someone with 
sequential section scores of “4”, “4”, “4”, and “4” would be 
in the same cluster as someone with only 3 months of high 
adherence (ie, sequential section scores of “NA”, “NA”, 
“NA”, and “4”). A clinician interpreting the cluster scores 
can be confident that the first individual has stable and high 
adherence over a 12-month period, whereas the second indi-
vidual only has 3 months’ worth of adherence data.
Practical examples of clustering 
adherence data using the algorithm-
based method
We present three examples to illustrate the use of our pro-
posed algorithm-based method to cluster adherence data. 
These examples are summarized in Table 1 and Figure 5. All 
the time-series charts displayed (Figure 5) are for illustrative 
purposes only and are not an essential component of the 
clustering process.
example A: low and declining adherence
Person A (Figure 5A) is in his early 40s and has chronic 
Pseudomonas in 2015 based on the Leeds definition.37 He has 
pancreatic insufficiency and CF-related diabetes. His best 
FEV
1
 in 2015 was 64% and he required 35 days of intrave-
nous antibiotics throughout 2015. His nebulized treatments 
prescription consisted of once-daily dornase alfa and twice-
daily colistimethate sodium alternating every 4 weeks with 
twice-daily tobramycin.
He has a complete 12 months’ worth of adherence data in 
2015 from the week beginning 04/01/2015 to week beginning 
27/12/2015, with an overall normative adherence of 38.0%. 
During the first 3 months of the period, his normative adher-
ence was 52.7%, but his subsequent 3-monthly adherence 
levels were 26.7%, 44.9%, and 27.5%. He therefore scored 
“3” for his first 3-month section and “2” for the next three 
sections. This indicates a trend of decline in his adherence. 
His mean cluster score is 2.25, which equates to an overall 
cluster of “2”. Given the trend of decline, his overall detailed 
cluster is therefore “2(-)”.
Person A therefore has a low adherence with a trend of 
decline in his adherence for the 12-month period through-
out 2015.
example B: low but improving adherence
Person B (Figure 5B) is in his mid-30s, has pancreatic insuf-
ficiency, and also has chronic Pseudomonas in 2015 based on 
the Leeds definition.37 His best FEV
1
 in 2015 was 78% and he 
required 33 days of intravenous antibiotics throughout 2015. 
He was on once-daily dornase alfa, along with twice-daily 
nebulized colistimethate sodium alternating every 2 weeks 
with twice-daily nebulized tobramycin.
He has a complete 12 months’ worth of adherence data in 
2015 from the week beginning 04/01/2015 to week beginning 
27/12/2015, with an overall normative adherence of 52.5%. 
During the first half of 2015, his 3-monthly normative adher-
ence levels were 41.0% and 46.2%. His adherence levels 
continue to improve throughout 2015 to 51.3% during the third 
quarter and 71.6% during the final quarter of 2015. He therefore 
scored “2” for both 3-month sections during the first half of 
2015 and “3” for both 3-month sections during the second half 
Table 1 Summary of the adherence clusters for the three example cases
Example Detailed scores (mean adherence) Overall 
cluster (mean 
adherence)
Interpretation
First 
quarter 
of 2015
Second 
quarter 
of 2015
Third 
quarter 
of 2015
Fourth 
quarter 
of 2015
Person A 3
(52.7%)
2
(26.7%)
2
(44.9%)
2
(27.5%)
2(-)
(38.0%)
Has 12 months’ worth of adherence data throughout 2015. Overall 
adherence is low, and there is a trend of declining adherence
Person B 4
(85.0%)
3
(74.7%)
3
(68.9%)
4
(90.3%)
3(o)
(79.7%)
Has 12 months’ worth of adherence data throughout 2015. Overall 
adherence is moderate. there is no clear adherence trend
Person C 2
(41.0%)
2
(46.2%)
3
(51.3%)
3
(71.6%)
2(+)
(52.5%)
Has 12 months’ worth of adherence data throughout 2015. Overall 
adherence is low, but there is a trend of improving adherence
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Figure 5 Weekly normative adherence time-series charts for the three example cases.
Note: 3(o), no clear adherence trend.
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of 2015. This indicates a trend of improvement in his adher-
ence. His mean cluster score is 2.5, which is rounded down 
to “2” for his overall cluster. Given the trend of improving 
adherence, his overall detailed cluster is therefore “2(+)”.
Person B therefore has an overall low level of adherence, 
but there is a trend of improving adherence during the 
12-month period throughout 2015. Compared to Person A, 
Person B’s adherence has a different trend, which illustrates 
the ability of the proposed clustering method to account 
for both the variation and magnitude of objective nebu-
lizer adherence.
example C: moderate adherence with no 
clear trend
Person C (Figure 5C) is in her early 20s and has chronic 
Pseudomonas in 2015 based on the Leeds definition.37 She 
has pancreatic insufficiency and CF-related diabetes. Her 
best FEV
1
 in 2015 was 65% and she required 30 days of 
intravenous antibiotics throughout 2015. Throughout 2015, 
she was on once-daily dornase alfa and twice-daily nebulized 
colistimethate sodium.
She has a complete 12 months’ worth of adherence 
data in 2015 from the week beginning 04/01/2015 to week 
beginning 27/12/2015, with an overall normative adher-
ence of 79.7%. During the first 3 months of the period, her 
normative adherence was 85.0%. Her 3-monthly adherence 
subsequently declined to 74.7% and 68.9%, before improving 
again to 90.3% during the last quarter of 2015. She therefore 
scored “4” for her first 3-month section, “3” for the next two 
sections, and “4” for the final section in 2015. This indicates 
no clear trend in her adherence over the 12-month period 
(initial decline followed by subsequent improvement). Her 
mean cluster score is 3.5, which is rounded down to “3” 
for her overall cluster. Given the lack of trend, her overall 
detailed cluster is therefore “3(o)”.
Person C therefore has a moderate adherence without a 
clear trend for the 12-month period throughout 2015. This 
example illustrates that it is possible to have relatively high 
overall nebulizer adherence of ~80%, yet there can be periods 
whereby adherence levels are relatively lower, hence the 
importance to understanding adherence over time.
Discussion
We have described a pragmatic algorithm-based clustering 
technique that can be used in real time and can also cluster 
adherence data with varying data duration. The clustering 
technique consists of three related steps: splitting the data 
into 3-monthly sections, scoring each section based on 
mean adherence, and aggregating the scores to determine 
the overall cluster. This clustering technique recognizes the 
two distinct groups of adherence archetype – consistently low 
adherence (“cluster 1”, very low adherence) and consistently 
high adherence (“cluster 4”, high adherence). “Cluster 2” 
(low adherence) and “cluster 3” (moderate adherence) have 
more ambiguous patterns on visual inspection, and adher-
ence data in those clusters can also display variation with 
time. “Cluster 2” and “cluster 3” are therefore separated into 
three different groups, each based on adherence trend (improv-
ing adherence, declining adherence, and no obvious trend).
Clustering of adherence data into the described categories, 
along with the “detailed” individual section scores, allows the 
adherence results and data completeness to be easily inter-
preted. In addition to potentially guiding the management of 
individual adults with CF, the categorization of adherence 
data also allows clinicians to gain a better understanding of 
the overall nebulizer adherence within their specialist CF 
centers. The usual summary measures for a continuous vari-
able (eg, mean or median) do not readily inform clinicians 
regarding the distribution of the adherence levels within 
their center. For example, it is possible to achieve a mean 
adherence of 50% if everyone in that center has adherence 
of 50%, but mean adherence of 50% can also be achieved if 
50% of the people in a particular center has mean adherence 
of 100%, while the other 50% has adherence of 0%. With 
the proposed clustering method, clinicians can identify the 
proportions of people in their center with “very low”, “low”, 
“moderate”, or “high adherence”. This also allows center 
comparisons using funnel plots to drive quality improvement 
initiatives,38,39 by comparing the proportion of high adherence 
for the different specialist CF centers.
The proposed algorithm-based clustering method can be 
automated; hence the clustering can be delivered within rou-
tine clinical practice via a software package. Objective adher-
ence data captured from routinely available chipped nebulizers 
should be stored in a secure data repository, and the data in 
a repository can then be clustered using a software package. 
We proposed clustering nebulizer data as a starting point 
since objective data can already be captured within routine 
clinical practice.14,15 CF is a multisystem condition; hence the 
treatments are also necessarily multimodal, including physio-
therapy for airway clearance, pancreatic enzyme replacement, 
nutritional supplementation, and management of CF-related 
diabetes.1 As technology advances, it is likely that most of the 
other CF treatments would also be chipped to routinely capture 
objective adherence data. For example, chipped airway clear-
ance devices and chipped pill bottles (eg, Medication Event 
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Monitoring System) have been used to objectively monitor 
adherence among people with CF in a research setting.40,41 
The algorithm we described is versatile and can also be used 
to cluster adherence data from other devices.
The proposed clustering method does have some limita-
tions. In studying variation over time, we proposed aggregat-
ing time-series adherence data into 3-monthly sections based 
on a balance between granularity and practicality. In addition, 
nebulized therapy in CF tends to have benefit that accumu-
lates over time rather than instantaneously, and 3 months is a 
credible period over which effects might be apparent. Theory 
dictates that time-series data aggregated over longer periods 
(eg, over months) will lose more information compared to 
fine-grained (eg, weekly) analysis.42,43 There is thus uncer-
tainty regarding the optimal period for aggregating adherence 
data to minimize information loss on data variation, and 
to avoid results being skewed by unpredictable short-term 
events, while keeping the clustering process simple enough. 
Similarly, there is also uncertainty regarding the optimal 
levels of scoring to assign to each 3-monthly section. We 
proposed an equal 4-level scoring system (from 1–4) because 
there is some evidence that adherence levels need to exceed 
75% for good health outcomes.9,22 With our proposed system, 
mean adherence of 26% is scored the same as mean adherence 
of 50%. Increasing the number of scores (eg, using a 10-level 
scoring system instead) or changing the width of each score 
band could provide greater granularity and identify more 
subgroups,20 but at the cost of increased complexity. It is 
crucial to acknowledge the need to achieve a balance between 
“lumping” and “splitting” in cluster analysis. Identifying 
many different subgroups may not be that useful if the differ-
ent subgroups behave similarly or respond similarly to differ-
ent treatments.44 A pragmatic way to resolve the uncertainty 
regarding the aggregation period, level of scoring, and total 
number of adherence clusters that is clinically useful would 
be to test the variations of the proposed clustering method 
(eg, 2-monthly aggregation instead of 3-monthly aggregation, 
or scoring adherence over ten levels instead of four levels) 
in a well-defined prospectively collected adherence dataset 
linked to health outcomes. Indeed, the nebulizer adherence 
intervention randomized control trial funded by the National 
Institute of Health Research45 would provide a suitable dataset 
for fine-tuning the proposed clustering method.
In conclusion, we have proposed a pragmatic clustering 
method for objective nebulizer adherence data that could 
potentially improve the understanding of the relationship 
between adherence and health outcomes, allow center com-
parison with funnel plots, and also guide clinical decisions 
when monitoring adherence. Cluster analysis of adherence 
data in CF has been attempted using self-report data.46 The 
advantages of using objective adherence data for clustering 
include better accuracy and the ability to study adherence 
variability in detail.8,26 There is uncertainty regarding some of 
the parameters chosen for this proposed method of clustering, 
but these parameters can be fine-tuned using a well-defined 
adherence dataset linked to health outcomes.
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